ABSTRACT SARCOSIN, also named Krp1, has been identified as a protein exclusively expressed in striated muscle tissue. Here we report on the role of SARCOSIN in skeletal muscle development and differentiation. We demonstrate, by means of whole-mount in situ hybridization, that Sarcosin mRNA is expressed in the myotome part of the mature somites in mouse embryos from embryonic day 9.5 onwards. Sarcosin is not expressed in the developing heart at these embryonic stages, and in adult tissues the mRNA expression levels are five times lower in the heart than in skeletal muscle. SARCOSIN protein partially co-localizes with the M-band protein myomesin and between and below laterally fusing myofibrils in adult skeletal muscle tissue. RNA interference mediated knock-down of SARCOSIN in the C2C12 myoblast cell line appeared to be stimulatory in the early phase of differentiation, but inhibitory at a later phase of differentiation.
Introduction
SARCOSIN, also named kelch related protein 1 (Krp1) was originally identified and described to be exclusively expressed in sarcomeric muscle (Taylor et al., 1998) . Northern hybridization experiments revealed high expression in adult human skeletal and heart muscle, with lower levels of expression in prostate muscle. The levels in skeletal muscle were found to be about 15 fold greater than the levels in cardiac muscle. No hybridization was detected in muscle samples from uterus, colon, intestine, bladder and stomach (Taylor et al., 1998) .
In skeletal muscle differentiation, important processes take place such as withdrawal from the cell cycle, fusion, de novo myofibrillogenesis and myotube formation that do not occur in primary cardiomyocyte cultures but the function of SARCOSIN in these processes is relatively unknown.
Skeletal muscle originates from the mesoderm. During embryonic development, paraxial mesoderm is first present on either side of the neural tube and notochord after which it will undergo segmentation to form somites. The somites are further specified into NEBULIN (Spence et al., 2006) , an actin-binding protein thought to function as a 'ruler' to regulate the precise lengths of the actin (thin) filaments in skeletal muscle (Witt et al., 2006) . Also, NEBULIN can interact with the intermediate filament DESMIN, possibly laterally linking Z-lines and integrating myofibrils with the cell membrane (Bang et al., 2002) . SARCOSIN further can be a binding partner of Nebulin-related anchoring protein (N-RAP), an actin-binding protein expressed in skeletal and cardiac muscle tissues (Lu et al., 2003) . N-RAP is expressed in the regions where actin-bundles link myofibrils to the cell membrane (Herrera et al., 2000; Zhang et al., 2001) . In embryonic cardiac cells N-RAP is associated with premyofibril structures and newly formed mature myofibrils (Lu et al., 2005) , while in skeletal muscle it has been identified in developing myofibrillar structures, but not in mature myofibrils (Lu et al., 2008) .
Immunofluorescence staining in cultured chick cardiomyocytes showed localization of SARCOSIN between narrow myofibrils that appear to be fusing laterally (Lu et al., 2003) . SARCOSIN knock-down by RNAi in cultured mouse embryonic cardiomyocytes resulted in an a-ACTININ staining pattern that is characteristic of newly forming myofibrils suggesting that SARCOSIN affects the assembly and or maintenance of myofibril structure (Greenberg et al., 2008) . Very recently, it was described that SARCOSIN expression is upregulated in C2 cells differentiating to myoblastst. Intriguingly, both knockdown and overexpression of SARCOSIN in these cells inhibited myoblast differentiation (Paxton et al., 2011) .
Besides its expression in striated muscle, SARCOSIN was also up-regulated in v-Fos transformed rat fibroblasts which became invasive and underwent extensive cytoskeletal reorganizations forming long pseudopodia. SARCOSIN localized at the tip of these pseudopodia, and while over-expression of SARCOSIN resulted in elongated pseudopodia, small interfering RNA (siRNA) mediated down-regulation caused shortening of these structures. The function of SARCOSIN in pseudopodia elongation is dependent on the binding of SARCOSIN to LIM and SH3 protein (LASP-1) (Spence et al., 2000; Spence et al., 2006) . LASP-1 is expressed in almost all adult mouse tissues and over-expressed in human breast cancers (Schreiber et al., 1998a; Tomasetto et al., 1995) . Interestingly, LASP-1 also contains two nebulin repeats, binds to non-muscle F-actin in vitro and is localized to focal adhesions and pseudopodia (Chew et al., 2002; Lin et al., 2004; Schreiber et al., 1998b) . A specific role for LASP-1 in muscle has not been described.
In this study the expression of Sarcosin mRNA during mouse embryonic development was visualized by whole-mount in situ hybridization (ISH) and SARCOSIN protein expression in adult skeletal muscle by immunofluorescence. SARCOSIN's role in the differentiation of skeletal muscle cells was studied by siRNA mediated down-regulation of SARCOSIN in the C2C12 myoblast cell line, which is an established cell line to study myogenesis.
Results

Sarcosin mRNA is expressed in the somites during mouse embryonic development
In order to investigate the expression of Sarcosin during development we performed whole-mount ISH on mouse embryos. Sarcosin mRNA was first observed in embryonic day (E)9.5 embryos, and expression was exclusively observed in the oldest somites (Fig .1A,  B) . At E10.5 Sarcosin mRNA was expressed in all somites (Fig. 1C) .
In contrast to what we expected, Sarcosin was not expressed in the embryonic heart during the period examined (E8-E10.5). Sagittal sections of whole-mount ISH of E9.5 embryos demonstrated Sarcosin expression in what is most likely the myotome part of the somites (Fig. 1D) . In transverse sections, the Sarcosin label was too weak to determine its localization with certainty (data no shown). Whole-mount ISH was performed on embryos from E8.5-E10.5. At those stages, the only Sarcosin expression observed was in the somites, no expression was observed in other skeletal muscle tissue such as cranial or pharyngeal muscle. Quantitative real-time PCR analysis demonstrated expression in mouse adult heart and skeletal muscle, with expression levels of Sarcosin mRNA in the heart being approximately five times lower compared to skeletal muscle expression (Fig. 1E) .
SARCOSIN is localized between laterally fusing myofibrils in adult skeletal muscle
The localization of SARCOSIN protein in adult skeletal muscle was determined using immunofluorescence. For orientation within the muscle, Z-discs were visualized by a-ACTININ staining ( Fig. 2 A-D) and M-bands by MYOMESIN staining (Fig. 2 E-H) . In adult skeletal muscle tissue an overall staining of SARCOSIN was observed, and SARCOSIN partially co-localized with the M-band protein MYOMESIN (Fig. 2 F-G) and was localized between (Fig  2B,D) and below laterally fusing myofibrils (Fig. 2 C,D) . Stainings with isotype control antibodies were negative (data not shown). (arrowhead). d, dorsal; v, ventral; a, anterior; p, posterior (Fig. 3C ). At day three of differentiation, Zbodies were visible and a colocalization of a-ACTININ and SARCOSIN was observed in these Z-bodies. In fused immature myofibrils on day 5 of differentiation SARCOSIN was equally distributed (Fig. 3C ).
RNAi mediated knock-down of SARCOSIN expression in C2C12 myoblasts
In order to establish the function of SARCOSIN in skeletal muscle cells, Sarcosin expression was downregulated in C2C12 cells. Proliferating C2C12 myoblasts were transfected with stealth siRNA to Sarcosin or with a mock-control, and 48 hrs after transfection differentiation Confocal imaging at planes above and below the laterally fusing myofibrils revealed that SARCOSIN was not only concentrated between fusing myofibrils but also underneath these structures. SARCOSIN did not colocalize with a-ACTININ.
Sarcosin is highly up-regulated in C2C12 myoblast differentiation into myotubes C2C12 cells were used to investigate the role of SARCOSIN in skeletal muscle. Sarcosin mRNA levels were readily detectable in undifferentiated myoblasts (day 0), and expression levels were highly up-regulated (approximately 60 fold) in day 6 differentiated myotubes compared to proliferating myoblasts (Fig. 3A) . Immunoblot analysis of SARCOSIN protein expression during myoblast differentiation confirmed the results observed with quantitative real-time PCR (Fig. 3B ). SARCOSIN protein was present in proliferating myoblasts and expression was up-regulated during differentiation of the myoblasts to myotubes. At the beginning of myoblast differentiaton a down-regulation of SARCOSIN protein was observed compared to proliferating myoblasts;
was induced by replacing the culture medium with differentiation medium containing 2% horse serum (Fig. 4A) . Sarcosin knock-down was evaluated using quantitative real time PCR and immunoblot analysis. Two days after transfection Sarcosin mRNA levels were decreased to approximately 30% compared to the mock-control transfected cells and this decrease persisted during at least 8 days after transfection (6 days differentiation) (Fig. 4B) . No nonspecific inhibitory effects were observed, in terms of cell death, cell morphology or Sarcosin expression. As expected, a decrease of SARCOSIN protein levels was somewhat delayed when compared to mRNA expression levels. Starting at day 3 of myoblast differentiation and thus 5 days after transfection, SARCOSIN protein levels were substantially decreased in siRNA transfected cells compared to their mock-controls (Fig. 4C) . No difference was observed between the morphology of the myotubes in cells transfected with siRNA compared to their mock-control (Fig. 4D) . In fact, both in siRNA transfected myoblasts and in the mock-controls spontaneously contracting myotubes were observed. However, when we analyzed myotube fusion by determining the numbers of nuclei per cells in time we observed a small reduction in the percentage of cells with more than 5 nuclei at day 4 of differentiation after Sarcosin knockdown ( Fig. 4E ) suggesting an inhibition of differentiation. Interestingly, at day 2 of differentiation a small increase in cells with 2 nuclei was observed ( Fig. 4E) after Sarcosin knockdown indicating an initial enhanced differentiation. Although this pattern was observed in 3 independent experiments, there was a substantial variation in the numbers of nuclei per myotubes between three independent experiments.
To assess the effects of SARCOSIN knock-down on C2C12 myoblast differentiation, the expression of genes involved in myofibril function was analyzed by quantitative RT-PCR. Expression levels of Lasp-1 (Fig. 5A ), coding for a binding partner of SARCOSIN that is involved in cell-migration (Spence et al., 2006) , decreased during differentiation of C2C12 cells to myotubes. On days 4 and 6 of differentiation, Lasp-1 transcript levels were significantly increased in cells treated with Sarcosin siRNA when compared to the mock-controls, although differences were minor and may not have biological significance. N-RAP is involved in myofibril assembly and was identified as a binding partner of SARCOSIN (Dhume et al., 2006; Lu et al., 2003) . Transcript levels of N-rap increased considerably (up to 16 times) during myoblast differentiation (Fig. 5B ). Between days 2 and 4 of myoblast differentiation N-rap transcript levels in siRNA transfected cells were up-regulated compared to their mock-controls and this up-regulation was significant on day 2 of differentiation. aActinin and Nebulin code for two building blocks of the sarcomeric structures (Clark et al., 2002) and their expression was highly upregulated during myoblast differentiation (Fig. 5 C,D) . a-Actinin transcript levels were readily detectable in proliferating myoblasts, and transcript levels were up-regulated in Sarcosin siRNA transfected cells compared to their mock-controls between days 2 and 4 of myoblast differentiation, this up-regulation was significant on day 3 of differentiation ( Fig. 5C ). Nebulin mRNA levels could only be detected reliably as of day 2 of myoblast differentiation and Nebulin transcript levels were up-regulated in siRNA transfected myoblasts compared to their mock controls between day 2 and 4 of myoblast differentiation (Fig. 5D) .
RNA expression levels were measured for 3 isoforms of myosin heavy chain (MHC). Embryonic-mhc is expressed in developing (Fig. 5E ). MHC2B is expressed in fast-twitching muscle and Mhc2b transcript levels increased up to 12 times during myoblast differentiation (Fig. 5F ). Finally, Non-muscle Mhc2b, coding for the myosin present in premyofibril structures before replacement with muscle myosin, decreased during myoblast differentiation (Fig.  5G) . Of these myosins, only Mhc2b transcripts were consistently up-regulated in siRNA treated myoblasts compared to their mock controls.
To examine whether SARCOSIN is involved in muscle atrophy Atrogin mRNA expression levels were measured. No difference in mRNA expression levels were observed between SARCOSIN down-regulated cells and their mock controls (Fig. 5H) .
Protein expression in differentiating myoblasts in which SAR-COSIN was down-regulated by siRNA treatment was analyzed by immunoblotting (Fig. 6A) . No major differences when differentiated cells were compared (Fig. 6A) . There appeared to be a weak upregulation of a-ACTININ and MYOGENIN expression during early differentiation. Although this upregulation was observed in several independent experiments (not shown) the significance is not known. Immunofluorescence analysis of the myotubes in which SARCOSIN was down-regulated did not reveal any disruption or difference in myotube formation as studied by a-ACTININ staining (Fig. 6B) .
Discussion
SARCOSIN is a protein exclusively expressed in sarcomeric muscle and is described to play a role in late myofibril assembly in cultured cardiomyocytes. SARCOSIN's role in skeletal myoblast differentiation is unknown (Greenberg et al., 2008; Taylor et al., 1998) .
To identify the role of SARCOSIN in skeletal muscle, expression of Sarcosin mRNA during early mouse embryonic development was analyzed. Sarcosin mRNA expression was first observed in the myotome part of mature somites in E9.5 embryos. This late expression during somite development implicates that Sarcosin expression is not necessary for initial somite formation from the paraxial mesoderm. Whether SARCOSIN plays a role in somite epithelialization and somite segmentation into the sclerotome and myotome remains to be determined (for review on somitogenesis see (Kalcheim and Ben-Yair, 2005 ) and references therein). Remarkably, Sarcosin mRNA was not expressed in the early embryonic heart (E8-E10.5) while at these embryonic stages the heart is contracting and thus functional sarcomeres are present. It is possible that the Sarcosin mRNA levels in the heart are below the detection limit for ISH at these embryonic stages. In adult tissues Sarcosin mRNA was expressed at a lower level in the heart compared to skeletal muscle as was previously demonstrated (Taylor et al., 1998) . Knockout studies in mice will help reveal the role of SARCOSIN in somite maturation and in heart development.
SARCOSIN protein is expressed throughout the cytoplasm and is concentrated between laterally fusing Z-discs of nascent myofibrils in cultured cardiomyocytes (Greenberg et al., 2008; Lu et al., 2003) . We observed a similar protein localization pattern in mouse adult skeletal muscle. SARCOSIN was also concentrated underneath laterally fusing myofibrils in adult skeletal muscle, and SARCOSIN partially co-localized with the M-band protein MYOMESIN. This expression pattern suggests that SARCOSIN has a function in the lateral fusion of myofibrils in skeletal muscle. A similar function for SARCOSIN in cultured cardiomyocytes has been reported (Greenberg et al., 2008) . In differentiating C2C12 cells we observed SARCOSIN distributed rather evenly throughout the cytoplasm which indeed has been described very recently (Paxton et al., 2011) , suggesting different functions for SARCOSIN in developing and adult muscle cells.
In proliferating C2C12 myoblasts SARCOSIN was already expressed at considerable levels, which is in contrast to results from Paxton et al., (2011) who observed absence of SARCOSIN (Krp1) expression in proliferating C2 cells. This could indicate that in our experiments some cells were already differentiating in the growth medium. On the other hand, the observed initial downregulation of SARCOSIN during the early phases of directed differentiation suggests different roles for SARCOSIN in proliferating cells versus its function in differentiating cells. Paxton and colleagues further reported that SARCOSIN was only expressed in cells that also expressed MYOGENIN, and suggested that MYOGENIN expres- In our experiments however SARCOSIN expression was observed even in the absence of MYOGENIN expression, which argues against such a hierarchy. Paxton and coworkers observed that overexpression of SARCOSIN in differentiating C2 cells reduces cell numbers, but whether this reduction also occurred in proliferating cells in growth medium is not known (Paxton et al., 2011) . In this study, protein expression was detected with immunoblot analysis. It is possible that because of the method used the protein levels in the samples do not reflect the total amount of proteins in the cells particularly for cytoskeletal elements and myofibrils. However, both a-ACTININ (Fig. 3B) and MYOSIN (Fig. 6A) were detected using immunoblot analysis. Since all cell lysate samples were treated similarly, we are of the opinion that the different samples can be mutually compared. Indeed protein levels of b-ACTIN as detected with immunoblot analysis were similar between samples where similar amounts of protein were analyzed (Fig. 3B) . In ad-
In addition, immunoblots with lysed samples that were not centrifuged before electrophoresis yielded similar results (data not shown).
To test whether SARCOSIN functions in myoblast differentiation and fusion, SARCOSIN expression levels were down-regulated in C2C12 cells using siRNA. During differentiation, RNA expression levels of sarcomeric proteins and binding partners of SARCOSIN were measured using quantitative real-time PCR in siRNA treated cells and compared to their mock controls. During skeletal muscle differentiation the mRNA levels of N-rap, a-actinin, Nebulin, Embryonic-mhc and Mhc2b were highly up-regulated. RNA expression levels from these sarcomeric proteins were higher in the siRNA treated cells compared to their mock controls starting from day 2 of differentiation, suggesting that knock-down of SARCOSIN affected differentiation. In agreement with this, a-ACTININ, MYOSIN and MYOGENIN protein levels were slightly increased at day 2 of differentiation compared to their mock controls. Indeed at day 2 of differentiation we observed more C2C12 cells with 2 nuclei after Sarcosin knockdown, indicating a weak enhanced early differentiation. However, SARCOSIN is not essential for myotobe differentiation since we did observe spontaneously contracting myotubes after differentiation of C2C12 cells in which Sarcosin expression was downregulated. Also, no difference in a-ACTININ localization was observed in differentiating C2C12 cells with downregulated Sarcosin expression (Fig. 6B) . Promoter analysis studies have revealed two pairs of E-boxes upstream of the Sarcosin coding sequence, suggesting that Sarcosin is a myogenic target (Paxton et al., 2011) . Based on its expression in differentiating C2 cells, combined with knockdown and overexpression experiments it has been suggested that SARCOSIN (Krp1) has functions in myogenesis before myofibrillar formation (Paxton et al., 2011) . The localised expression that we observed in mature muscle cells suggests an additional function in mature myofibers.
Very recently it has been described that both knockdown and overexpression of Sarcosin (Krp1) resulted in reduced myoblast differentiation (Paxton et al., 2011) . We found similar results as we observed a reduced percentage of cells with more than 5 nuclei after Sarcosin knockdown in C2C12 cells. Taken together, it appears that Sarcosin at the first phases of myoblast differentiation has an inhibitory function, while at later stages of differentiation it has a stimulatory action. This could explain the paradoxical inhibition of differentiation observed after both knockdown and overexpression of Sarcosin (Paxton et al., 2011) . Although Sarcosin expression is highly upregulated in differentiating skeletal muscle cells, its presence does not seem to be essential for the differentiation process itself. Rather, it might be that SARCOSIN is important for the correct functioning of skeletal muscle cells, as suggested by the expression of SARCOSIN in adult skeletal muscle.
Materials and Methods
Animals
C57Bl/6 mice were intercrossed and the time of feritilization was taken as the midpoint of the darkcycle before the copulation plug was found. Females were sacrificed for collection of embryos at various time points. Embryos were fixed in 4% (w/v) paraformaldehyde (PFA) (Electron Mi-(Electron Microscopy Science, Hatfield, PA) in phosphate buffered saline (PBS, Braun, Melsungen, Germany) at 4°C overnight and stored in 100% methanol at -20 ºC. All animal handling procedures were approved by the institutional animal experiments committee.
Whole-mount in situ hybridization
Whole-mount in situ hybridization (ISH) was performed as described previously (Wilkinson, 1992) . For probe preparation, purified PCR product was generated to use as a template, with Sarcosin-specific primers (forward: 
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CCTTACCCAGGTTCCTCACA, reverse: CCAATCTTAGGATGGCCAGA) with the T3 promoter sequence (ATACAATTAACCCTCACTAAAGGG) at the 5'end of the forward primer and the T7 promoter sequence (ATAG-GTAATACGACTCACTATAGGGC) at the 3'end of the reverse primer. RNA probes were synthesized using T7 (antisense) polymerase and DIG labelled nucleotides according to the manufacturer's protocol (Roche Applied Sciences, Almere, The Netherlands). Embryos were imaged using a Zeiss Axioplan SZX9 coupled to a Leica DFC480 digital camera.
Cell culture and transfection
The murine myoblast cell line C2C12 (ATCC CRL-1772) was cultured at 37ºC, 5% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM-HG, Invitrogen, Carlsbad, CA) based proliferation medium supplemented with 10% fetal bovine serum (FBS, Invitrogen), 1x non-essential amino acids (Invitrogen) and 50 U/ml penicillin and 50 mg/ml streptomyocin (Invitrogen). Myotube formation was induced by replacing FBS in the culture medium with 2% horse serum (Differentiation medium, Vector Laboratories, Burlingame, CA). To reduce endogenous SARCOSIN expression, cells were transfected with stealth siRNA duplex oligoribonucleotides against Sarcosin (5'-CCACT-GAAGTCAATGACATATGGAA-3') (Invitrogen) using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Universal control siRNAs (Invitrogen) with GC percentage similar to the Sarcosin stealth siRNA were used as a negative control. This is referred to as 'mock control' or 'mock' throughout the manuscript. Briefly, one day before transfection cells were plated at a density of 4000 cells/cm 2 on gelatin-coated dishes in proliferation medium. Cells were transfected with 40 pmol/ml Sarcosin siRNA and medium was changed 8 hrs after transfection. Differentiation was induced 48 hrs after transfection.
RNA isolation and quantitative real-time PCR
Total RNA of C2C12 cells was extracted using the RNeasy minikit (Qiagen, Valencia, CA) and on-column DNAse treatment (Qiagen) was performed. Total RNA from adult mouse heart and skeletal muscle was isolated using Trizol reagent (Invitrogen). Total RNA was reverse transcribed using Superscript II reverse-transcription polymerase (Invitrogen) and random primers (Invitrogen) according to the supplier's protocol.
For quantitative real-time PCR, each reaction contained 10 ml SYBRGreen Mastermix (BIO-RAD, Hercules, CA), 0.5 mM forward primer, 0.5 mM reverse primer and 1 ml cDNA as a template in a final volume of 20 ml. Primers were designed using Primer 3 software (Rozen and Skaletsky, 2000) or based on literature (Table 1) (de Jonge et al., 2007; Dhume et al., 2006; Martinez-Fernandez et al., 2006; Sakiyama et al., 2005; Sultan et al., 2006; Willems et al., 2006) . Reactions were carried out in duplicate for each sample. Negative controls were reactions containing template synthesized without reverse transcriptase and reactions containing H 2 O instead of cDNA. The reactions were amplified on a MyIQ Real-Time PCR detection system (BIO-RAD) using the following program: initial denaturation at 95ºC for 3 min, followed by 40 cycles of 30 sec at 95ºC, 30 sec at the corresponding annealing temperature (Table 1) and 30 sec at 72ºC. Melting curves were produced to verify single PCR product amplification. Efficiency of the PCR reactions was tested using standard curves synthesized from either a dilution series of cDNA or PCR product. PCR products were separated on 1% agarose gels against a 100 bp ladder and visualized with ethidium bromide. To verify the specificity, the PCR products were Using ge-Norm, gene expression normalization factors for each sample were calculated based on the expression levels of the reference genes glyceraldehyde-3-phosphate dehydrogenase (Gapdh), phosphoglycerate kinase 1 (Pgk1), and beta-actin (B-actin) for data in Fig. 1 , and to the expression levels of Ornithine decarboxylase antizyme 1 (Oaz1), ribosomal protein l22 (Rpl22) and Gapdh for data in Figs. 3-5. The underlying principles and calculations used are described in (Vandesompele et al., 2002) . Each experiment was performed 3 times independently (biological replicates) and gene expression detection of each sample was performed twice (technical replicate). Statistical differences between expression levels were tested using a nonparametric Mann-Whitney test. Differences were considered significant at P<0.05.
Protein isolation and immunoblotting
To prepare protein cell extracts C2C12 cells were washed with ice cold PBS and lysed in buffer containing 140 mM NaCl, 50 mM Tris-HCL pH7.5, 1 mM EDTA, 0.1% Triton X-100, 10% Glycerol and protease inhibitor cocktail (1 tablet per 50 ml lysis buffer) (Roche Applied Sciences). Cell lysates were clarified by centrifugation at 10,000 rpm and 4ºC for 15 min and the supernatants protein contents were measured using a DC-protein assay (BIO-RAD). Equal concentrations of protein were suspended in Laemmli's sodium dodecylsulfate-(SDS) sample buffer. Protein samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to Trans-Blot nitrocellulose transfer membrane (BIO-RAD). Membranes were blocked using 5% Blotting Grade Blocker non-fat dry milk (BIO-RAD) in 1x Tris Buffered Saline-0.1% Tween (TBST) for 1 hr at room temperature (RT) and subsequently probed with primary antibody (Table 2) overnight at 4ºC. Next the membranes were incubated with 1 to 10,000 dilution of either horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr at RT. Signals were visualized using SuperSignal West Dura Extended Duration Substrate (Pierce, ThermoScientific, Erembodegem, Belgium) and exposure to X-ray film (Fuji, Dusseldorf, Germany) or detected with a ChemiDoc XRS system (BIO-RAD).
Immunofluorescence staining and microscopy
C2C12 cells cultured on gelatine-coated glass cover slips and frozen tissue sections of mouse skeletal muscle and heart tissue were fixed in 4% PFA for 10 min at RT. C2C12 cells were permeabilized after fixation for 8 min using 0.1% Triton X100 in PBS. Slides were blocked in PBS-0.1% Tween 20 containing 4% normal goat serum (PBST) for 1 hr at RT. For staining cells were incubated overnight at 4ºC with primary antibody (Table  2) , and subsequently incubated for 1 hr at RT with secondary antibodies: goat anti-mouse Alexa488-conjugated and goat anti-rabbit Alexa568-conjugated (1:200, Invitrogen). The antibodies were diluted in PBST and rabbit and mouse isotypes served as negative control. Slides were mounted in Fluosave mounting medium (Calbiochem, Merck Chemicals Ltd, Nothingham, UK) and analyzed by normal fluorescence or confocal laser scanning microscopy.
Myotube quantification
Myotubes were visualized using a-actining immunofluorescent staining while the nuclei were stained using Topro. For each differentiation day and for both the mock control and siRNA treated cells myotubes in 6 microscopic fields were scored in a blinded fashion for the number of nuclei present in each myotube.
